Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder (NMOSD): a Multi-Center, Phase 2 Trial (EASE-NMO)

NCT07184840 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.

NCT NCT07184840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07184840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder (NMOSD): a Multi-Center, Phase 2 Trial (EASE-NMO)
Lead sponsor
Tianjin Medical University General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 9, 2025
Completion date
September 30, 2026
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder attack